Corrine Stahura, PharmD, and Sophia Gilardone, PharmD, BCOP, discuss recent clinical trial data and evolving guideline recommendations for HER2- and HER3-directed antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC), highlighting differences in efficacy, safety, and patient selection criteria.
Corrine Stahura, PharmD; and Sophia Gilardone, PharmD, BCOP, discuss how patient- and treatment-related factors influence the risk of severe toxicity with antibody-drug conjugates (ADCs) in non–small cell lung cancer (NSCLC).
Corrine Stahura, PharmD; and Sophia Gilardone, PharmD, BCOP, discuss the distinct adverse effect profiles of HER2- and HER3-targeted antibody-drug conjugates—particularly the risk and management of interstitial lung disease—and offer practical guidance based on clinical trial data and treatment protocols.
Cynthia Ryan, PharmD, BCPS, discusses practical, evidence-based strategies for pharmacists to identify, prevent, and manage dermatologic toxicities associated with cancer therapies, emphasizing interdisciplinary collaboration, patient education, and proactive supportive care to improve adherence and outcomes.
Specialty pharmacists are critical for enhanced management of clinical and logistical aspects of treatment.
Nadine Barrett, PhD, MA, MPH, discusses the role of international collaborations to advance global cancer care access.
The new virtual resource will support multidisciplinary cancer care teams by preparing, implementing, and evaluating electronic health record integrations for biomarker testing.
Kristin Ferguson, DNP, RN, OCN, outlined 4 principles for the reimbursement of oncology drugs, diagnostics, and biomarker testing that were recently released by the Association of Community Cancer Centers.
Kirollos Hanna, PharmD, BCPS, BCOP, assistant professor of pharmacy at the Mayo Clinic College of Medicine and the oncology pharmacy manager at M Health Fairview - Maple Grove, discusses the potential impact of ACCC's Multiple Myeloma Dispensing Project on the field.
Oncologist Susan Miesfeldt, MD, of MaineHealth, discussed the importance of genetic testing and counseling for breast and ovarian cancers as well as barriers that must be addressed in order to reach more patients eligible for these services.
Immunotherapies will continue to change standards of care for treatment of RCC.
Medication reconciliation is a critical component of the oncology pharmacistʼs duties that has been performed safely over the phone with the patient, caregiver, and pharmacy with the assistance of electronic health records.
Pharmacy Times interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers, about how the COVID-19 pandemic is going to impact cancer mortality.
Pharmacy Times interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers, about how screening can help reduce cancer deaths.
Pharmacy Times interviewed Randall A. Oyer, MD, president of the Association of Community Cancer Centers about the effect of coronavirus disease 2019 (COVID-19) on cancer clinical trials.
Topics covered in-depth in the show include strategies for patient education, cancer team coordination, side effect monitoring and management of medications from both in-house and external specialty pharmacies.
Pharmacy Times®, the leading multimedia resource for pharmacy professionals, adds the Association of Community Cancer Centers to its Strategic Alliance Partnership program.
Christian G. Downs, JD, MHA, executive director of the Association of Community Cancer Centers, discusses cancer politics and policy today.
Ali McBride, PharmD, BCOP, president of the Association of Community Cancer Centers, discusses how pharmacists can assist in adverse event management during the American Society of Clinical Oncology Annual Meeting in Chicago, IL
Ali McBride, PharmD, BCOP, president of the Association of Community Cancer Centers, discusses the key takeaways from the ASCO 2019 meeting and the important information that pharmacists should be aware of during the American Society of Clinical Oncology Annual Meeting in Chicago, IL
During the American Society of Clinical Oncology Annual Meeting in Chicago, IL, Ali McBride, PharmD, BCOP, president of the Association of Community Cancer Centers, discusses how growth in the oncology space will affect how pharmacists practice.
Mark S. Soberman, MD, MBA, FACS, the 2017 to 2018 President of the Association of Community Cancer Centers (ACCC), discusses his vision for the next-generation of multidisciplinary care in an interview during the 2017 ASCO Annual Meeting.
